Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

NCT05456256 is registered in ClinicalTrials.gov with Lantern Pharma Inc. as lead sponsor.

NCT NCT05456256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05456256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
Lead sponsor
Lantern Pharma Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2023
Completion date
June 30, 2027
Enrollment
90 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, carcinoma, non-small-cell lung